Long-Term Results After Sleeve Gastrectomy for Gastroesophageal Reflux Disease: a Single-Center French Study
Autor: | François Dalmay, A. Iannelli, Muriel Mathonnet, Etienne Chuffart, Maxime Sodji |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty Sleeve gastrectomy Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes Gastroenterology 03 medical and health sciences 0302 clinical medicine Quality of life Weight loss Gastrectomy Internal medicine Surveys and Questionnaires Weight Loss medicine Humans Postoperative Period Retrospective Studies Nutrition and Dietetics business.industry Retrospective cohort study Middle Aged medicine.disease humanities Obesity Morbid GERD Gastroesophageal Reflux Quality of Life 030211 gastroenterology & hepatology Surgery Female Laparoscopy France medicine.symptom business Dyslipidemia Follow-Up Studies |
Zdroj: | Obesity surgery. 27(11) |
ISSN: | 1708-0428 |
Popis: | Many studies have analyzed the impact of sleeve gastrectomy (SG) on weight loss and/or the evolution of obesity-related comorbid conditions, but few have reported the long-term outcomes after surgery. The objective of this study was to investigate the outcomes after SG on weight loss, obesity-related comorbid conditions, quality of life (QoL), and GERD symptoms (GERDS) beyond 5 years. A prospective database was retrospectively searched for the following factors: gender, age, anthropometrics, presence of comorbid conditions, QoL (BAROS questionnaire), and presence of GERDS. The data were analyzed before and at 1 and 6 years after surgery. Of the 64 patients included, 32.8% were lost to follow-up (76% during the first postoperative year). A complete follow-up of >5 years was obtained for 41 patients. Before surgery, mean excess BMI was 22 ± 7 kg/m2, and 26.8% of patients had GERDS. Percent excess BMI loss was 55 ± 30% at 1 year and 48 ± 27% at 6 years. Preoperative BMI and absence of type 2 diabetes (T2D) before surgery were the only independent variables for long-term failure. Six years after SG, remission from metabolic comorbidities was as follows: 50% for T2D, 28% for blood hypertension, 58% for dyslipidemia, and 33% for sleep-apnea syndrome. Thirty percent of patients with preoperative GERD had resolution of symptoms at 6 years whereas 9 patients (32%) had de novo GERD. QoL was improved for 62% of patients at 6 years. The benefits of SG on weight loss, resolution of comorbidities, and QoL were maintained in the long term for most patients. |
Databáze: | OpenAIRE |
Externí odkaz: |